Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 987
countries
28
conditions
2 109

10 trials match your criteria

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tisagenlecleucel

Rheumatoid arthritis+1

Not yet recruiting

Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Secondary progressive multiple sclerosis+1

Not yet recruiting

Study on the Safety and Effects of YTB323 and Drug Combination in Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide

Relapsing multiple sclerosis

Not yet recruiting

Study on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Myasthenia gravis

Not yet recruiting

Study on the Safety and Effects of YTB323 and Drug Combination for Patients with Treatment-Resistant Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Acute lymphocytic leukaemia+6

Not recruiting

Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine

Systemic lupus erythematosus+1

Not recruiting

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.